Khiron Life Sciences closes marketed offering of units including full exercise of over-allotment option

1 minute read
04 April 2023

On April 4, 2023, Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) announced that it had closed its previously announced marketed public offering of units, including the exercise in full of the over-allotment option, for aggregate gross proceeds of $690,000. The offering was led by Canaccord Genuity Corp. as agent and sole bookrunner.

Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. 
Gowling WLG was counsel to Khiron in this transaction with a team that included Peter Simeon, Jacob Cawker and Ashley Andaya.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.